A method for producing derivatives of N-retinoylaminoalkane sulfonic acid, the method comprising providing retinoic acid, chloroformate, aminoalkanesulfonic acid selected from the group consisting of cysteic acid and alkyl ester thereof, cysteinesulfinic acid and alkyl ester thereof, homocysteic acid and alkyl ester thereof, homocysteinesulfinic acid and alkyl esters thereof, taurine and derivatives thereof, and an organic solvent, and a base, mixing said components under substantial absence of oxidizing compounds thereby forming a reaction mixture comprising a liquid phase, wherein the liquid phase is one phase and the derivatives of N-retinoylaminoalkane sulfonic acid are formed in said liquid phase.

Described herein are functionalized graphene compositions that have gas, fluid, and/or vapor resistant properties. Also described are barrier elements based on the aforementioned compositions. Also described is a barrier device that incorporates the barrier element and further comprises a substrate and a protective coating, encompassing the barrier element.

Described herein are functionalized graphene compositions that have gas, fluid, and/or vapor resistant properties. Also described are barrier elements based on the aforementioned compositions. Also described is a barrier device that incorporates the barrier element and further comprises a substrate and a protective coating, encompassing the barrier element.

The present disclosure relates to salts and polymorphs of aminoalkylfumagillol carbamates (e.g., fumagill-6-yl N-(trans-4-aminocyclohexyl)carbamate benzenesulfonic acid salt and fumagill-6-yl N-(trans-4-aminocyclohexyl)carbamate hydroxynaphthoic acid salt). The polymorphs are characterized by X-ray powder diffraction, differential scanning calorimetry, and thermogravimetric analysis, among other methods. The polymorphs and salts can be used as intermediates in the production of fumagillol derivatives (e.g., polymer-conjugated fumagillol derivatives) as well as therapeutic agents for the treatment of various diseases and conditions such as cancer.

A compound is of formula (I): ##STR00001##
in which A.sub.1 and A.sub.1 are independently from each other a linear or branched alkylene radical including from 1 to 20 carbon atom(s); A.sub.2 is in particular a linear or branched alkylene radical including from 1 to 200 carbon atom(s); A.sub.3 is H or a linear or branched alkyl radical including from 1 to 15 carbon atom(s) and R.sub.1 and R.sub.1 are independently from each other H or a linear or branched alkyl radical comprising from 1 to 20 carbon atom(s). The compounds of formula (I) can be used in particular for the preparation of poly(hydroxyurethane)s and epoxy resins.

A compound is of formula (I): ##STR00001##
in which A.sub.1 and A.sub.1 are independently from each other a linear or branched alkylene radical including from 1 to 20 carbon atom(s); A.sub.2 is in particular a linear or branched alkylene radical including from 1 to 200 carbon atom(s); A.sub.3 is H or a linear or branched alkyl radical including from 1 to 15 carbon atom(s) and R.sub.1 and R.sub.1 are independently from each other H or a linear or branched alkyl radical comprising from 1 to 20 carbon atom(s). The compounds of formula (I) can be used in particular for the preparation of poly(hydroxyurethane)s and epoxy resins.

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.